Skip to main content
. Author manuscript; available in PMC: 2018 Sep 5.
Published in final edited form as: FEBS Lett. 2012 Apr 19;586(10):1480–1487. doi: 10.1016/j.febslet.2012.04.001

Fig. 7. Paclitaxel blocks CRSBP-1 ligand-induced contraction of CRSBP-1-associated fibrillar structures in SVEC4–10 cells.

Fig. 7.

Cells were pretreated with vehicle only (DMSO) (panels A to I), 5 μM paclitaxel (panels J to R) for 1 h and then stimulated with vehicle only (panels A, B, C and panels J, K, L), 10 μM PDGF peptide (panels D, E, F and M, N, O) and 10 μM VEGF peptide (panels G, H, I and panels P, Q, R). After stimulation for 1 h, cells were fixed with methanol at −20°C for 10 min and stained with anti-CRSBP-1 serum and antibody to BiP. The bar indicates a scale of 10 μm (panel A). Arrowheads indicate the plasma membrane localization of CRSBP-1.